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Lupus Anticoagulant and Abnormal Coagulation 
Tests in Patients with Covid-19
To the Editor: Patients with coronavirus disease 
2019 (Covid-19) have a profound hypercoagu-
lable state, and complicating venous thrombotic 
events are common.1-3 Abnormalities in coagu-
lation screening measures, including a prolonged 
activated partial-thromboplastin time (aPTT), 
have been reported in patients with Covid-19.4 
This finding could be seen as a reason to avoid 
the use of anticoagulation at both therapeutic and 
prophylactic doses.
A prolonged aPTT may indicate a clotting-
factor deficiency or the presence of an inhibitor of 
coagulation that is either specific (e.g., antibody 
to factor VIII) or nonspecific (e.g., lupus antico-
agulant). Lupus anticoagulant can affect in vitro 
tests of blood coagulation but typically is not as-
sociated with bleeding. As part of the antiphospho-
lipid syndrome, lupus anticoagulant is associated 
with a thrombotic risk. We investigated the cause 
of prolonged aPTT in patients with Covid-19.
Blood specimens obtained from 216 patients 
who were positive for severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) were re-
ceived for coagulation screening, and 44 (20%) 
were found to have a prolonged aPTT. The speci-
mens from 9 patients were excluded, and those 
from 35 patients were investigated further. (De-
tails of the methods are provided in the Supple-
mentary Appendix, available with the full text of 
this letter at NEJM.org.)
A summary of the results is provided in Ta-
ble 1. The median age was 57 years, and 24 pa-
tients were male. Pulmonary embolism was con-
firmed in 1 patient, and clinically suspected 
thrombosis was present in 1 patient. No clinically 
significant bleeding or arterial thromboses were 
reported.
No patients were found to have deficiencies 
in factor VIII or factor IX. In 5 patients, marginal 
reductions in factor XI were found that were un-
likely to be of clinical significance. The factor 
XII level was 50 IU per deciliter or lower in 16 pa-
tients. Lupus anticoagulant assays were performed 
in 34 patients, and 31 (91%) were positive. The 
presence of lupus anticoagulant was indicated by 
two assays (dilute Russell’s viper-venom time 
[DRVVT] and lupus anticoagulant–sensitive aPTT) 
in 18 of 34 patients (53%), by DRVVT alone in 
7 (21%), and by lupus anticoagulant–sensitive aPTT 
alone in 6 (18%). All lupus anticoagulant–positive 
specimens had a prolonged aPTT with a 50:50 mix 
(i.e., in a sample made up of 50% patient plasma 
and 50% normal plasma).
In a historical control cohort of 540 specimens 
received for lupus anticoagulant testing, 43 (8%) 
had an aPTT of 30 seconds or longer, and 11 of 
the 43 (26%) were positive for lupus anticoagulant. 
The percentage of specimens that were positive for 
lupus anticoagulant was significantly higher 
among the patients with Covid-19 than in the con-
trol cohort (P<0.001) (see the Supplementary Ap-
pendix).
In our study, most patients with Covid-19 who 
were admitted to the hospital with a prolonged 
aPTT were positive for lupus anticoagulant (91%) 
and often had an associated factor XII deficiency. 
It is important to note that neither observation 
is associated with a bleeding tendency; factor XII 
is not required for hemostasis, and the presence 
of lupus anticoagulant, if persistent, can be associ-
ated with a thrombotic tendency within the an-
tiphospholipid syndrome. Further study is required 
to determine the role, if any, of lupus anticoagulant 
in the pathogenesis of Covid-19 thrombosis.
Although we detected heparin in 28 of the 35 
specimens, the DRVVT assay contains heparinase, 
which neutralizes any heparin effect that might 
lead to false positive detection of lupus anticoagu-
lant. An association between lupus anticoagulants 
and acquired factor XII deficiency secondary to 
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factor XII antibodies has been described previously. 
It is notable that the aPTT prolongation in the 
patients in our study was present despite sub-
stantial elevations in factor VIII, which shortens 
the aPTT.
We suggest that a prolonged aPTT should not 
be a barrier to the use of anticoagulation thera-
pies in the prevention and treatment of venous 
thrombosis in patients with Covid-19. In our opin-
ion, clinicians should not withhold use of antico-
agulants for thrombosis while awaiting further 
investigation of a prolonged aPTT, nor should they 
withhold thrombolytic therapy in the face of a 
high-risk pulmonary embolism on the basis of a 
prolonged aPTT alone.
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Table 1. Demographic and Clinical Characteristics and Laboratory Findings  
in 35 Patients with Covid-19 and a Prolonged aPTT.*
Characteristic or Finding
Value in Patients 
(N = 35)
Reference 
Range
Mean age (95% CI) — yr 56.6 (18.6–83.4) —
Male sex — no. (%) 24 (69) —
Taking oral anticoagulant at admis-
sion — no.
0 —
Thrombosis status — no. (%)
Arterial 0 —
Venous, confirmed 1 (3) —
Venous, suspected 1 (3) —
Mean (95% CI) values on coagula-
tion assay
aPTT — sec 35.5 (30.0–54.6) 21–29
PT — sec 11.8 (10.2–14.1) 8.8–11.7
aPTT 50:50 — sec 32.6 (29.0–38.0) 21–29
Factor VIII level — IU/dl 199 (100–369) 52–153
Factor IX level — IU/dl 125 (62–205) 58–138
Factor XI level — IU/dl 81 (37–144) 58–148
Factor XII level — IU/dl 55 (26–100) 52–164
Anti–factor Xa heparin activity on 
heparin assay — no. (%)
<0.05 IU/ml 7 (20) —
0.05–0.19 IU/ml 7 (20) —
0.20–0.40 IU/ml 14 (40) —
0.41–0.50 IU/ml 5 (14) —
>0.50 IU/ml 2 (6) —
LA test result†
Positive — no./total no. (%) 31/34 (91) —
DRVVT — no. 7 —
LA-sensitive aPTT — no. 6 —
Both tests positive — no. 18 —
Negative — no./total no. (%) 3/34 (9)‡ —
*  The abbreviation aPTT denotes activated partial-thromboplastin time, CI con-
fidence interval, DRVVT dilute Russell’s viper-venom time, LA lupus antico-
agulant, and PT prothrombin time.
†  Assays for lupus anticoagulant were performed with 34 of the specimens.
‡  The 3 specimens that were negative for lupus anticoagulant had levels of fac-
tor XII that were deemed sufficient to prolong the aPTT.
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